Shinpoong Pharmaceutical Co Ltd (019175) - Net Assets
Based on the latest financial reports, Shinpoong Pharmaceutical Co Ltd (019175) has net assets worth ₩270.73 Billion KRW (≈ $183.47 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩352.47 Billion ≈ $238.86 Million USD) and total liabilities (₩81.74 Billion ≈ $55.39 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Shinpoong Pharmaceutical Co Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩270.73 Billion |
| % of Total Assets | 76.81% |
| Annual Growth Rate | 3.2% |
| 5-Year Change | -23.64% |
| 10-Year Change | 24.85% |
| Growth Volatility | 24.34 |
Shinpoong Pharmaceutical Co Ltd - Net Assets Trend (2014–2025)
This chart illustrates how Shinpoong Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Shinpoong Pharmaceutical Co Ltd asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Shinpoong Pharmaceutical Co Ltd (2014–2025)
The table below shows the annual net assets of Shinpoong Pharmaceutical Co Ltd from 2014 to 2025. For live valuation and market cap data, see Shinpoong Pharmaceutical Co Ltd (019175) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩270.73 Billion ≈ $183.47 Million |
+4.90% |
| 2024-12-31 | ₩258.09 Billion ≈ $174.90 Million |
-4.69% |
| 2023-12-31 | ₩270.78 Billion ≈ $183.51 Million |
-18.13% |
| 2022-12-31 | ₩330.76 Billion ≈ $224.15 Million |
-6.71% |
| 2021-12-31 | ₩354.56 Billion ≈ $240.28 Million |
-5.28% |
| 2020-12-31 | ₩374.33 Billion ≈ $253.68 Million |
+79.00% |
| 2019-12-31 | ₩209.13 Billion ≈ $141.72 Million |
+0.79% |
| 2018-12-31 | ₩207.48 Billion ≈ $140.61 Million |
-1.25% |
| 2017-12-31 | ₩210.11 Billion ≈ $142.39 Million |
-3.11% |
| 2016-12-31 | ₩216.85 Billion ≈ $146.96 Million |
+11.28% |
| 2015-12-31 | ₩194.86 Billion ≈ $132.05 Million |
+1.75% |
| 2014-12-31 | ₩191.51 Billion ≈ $129.79 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shinpoong Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 68.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩50.77 Billion | 18.81% |
| Other Components | ₩219.20 Billion | 81.19% |
| Total Equity | ₩269.97 Billion | 100.00% |
Shinpoong Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Shinpoong Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lion Industries Corporation Bhd
KLSE:4235
|
$25.64 Million |
|
Censof Holdings Bhd
KLSE:5195
|
$25.65 Million |
|
Aytu BioScience Inc
NASDAQ:AYTU
|
$25.65 Million |
|
Cubic Korea Inc
KQ:021650
|
$25.66 Million |
|
Boundless Bio, Inc. Common Stock
NASDAQ:BOLD
|
$25.63 Million |
|
Pamapol S.A.
WAR:PMP
|
$25.63 Million |
|
Ovaro Kiinteistosijoitus Oyj
HE:OVARO
|
$25.62 Million |
|
Microbix Biosystems Inc.
TO:MBX
|
$25.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shinpoong Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 256,820,523,460 to 269,974,999,790, a change of 13,154,476,330 (5.1%).
- Net income of 8,825,117,550 contributed positively to equity growth.
- Other factors increased equity by 4,329,358,780.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩8.83 Billion | +3.27% |
| Other Changes | ₩4.33 Billion | +1.6% |
| Total Change | ₩- | 5.12% |
Book Value vs Market Value Analysis
This analysis compares Shinpoong Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.47x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4.35x to 3.47x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩4372.79 | ₩19000.00 | x |
| 2018-12-31 | ₩4303.11 | ₩19000.00 | x |
| 2019-12-31 | ₩4338.83 | ₩19000.00 | x |
| 2020-12-31 | ₩7577.91 | ₩19000.00 | x |
| 2021-12-31 | ₩7174.44 | ₩19000.00 | x |
| 2022-12-31 | ₩6689.68 | ₩19000.00 | x |
| 2023-12-31 | ₩5471.49 | ₩19000.00 | x |
| 2024-12-31 | ₩5212.40 | ₩19000.00 | x |
| 2025-12-31 | ₩5479.39 | ₩19000.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shinpoong Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.76%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 1.31x
- Recent ROE (3.27%) is above the historical average (-3.20%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 1.76% | 1.52% | 0.54x | 2.15x | ₩-15.66 Billion |
| 2015 | 0.76% | 0.75% | 0.48x | 2.12x | ₩-17.87 Billion |
| 2016 | -8.59% | -9.58% | 0.47x | 1.92x | ₩-40.25 Billion |
| 2017 | 0.43% | 0.49% | 0.48x | 1.84x | ₩-20.08 Billion |
| 2018 | 1.36% | 1.50% | 0.49x | 1.85x | ₩-17.84 Billion |
| 2019 | 2.56% | 2.81% | 0.50x | 1.83x | ₩-15.49 Billion |
| 2020 | 1.34% | 2.53% | 0.41x | 1.30x | ₩-32.33 Billion |
| 2021 | -3.28% | -6.12% | 0.48x | 1.11x | ₩-46.93 Billion |
| 2022 | -10.73% | -16.90% | 0.58x | 1.10x | ₩-68.34 Billion |
| 2023 | -21.26% | -28.63% | 0.57x | 1.30x | ₩-84.28 Billion |
| 2024 | -5.99% | -6.96% | 0.65x | 1.33x | ₩-41.07 Billion |
| 2025 | 3.27% | 3.76% | 0.67x | 1.31x | ₩-18.17 Billion |
Industry Comparison
This section compares Shinpoong Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $401,390,357,055
- Average return on equity (ROE) among peers: 0.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shinpoong Pharmaceutical Co Ltd (019175) | ₩270.73 Billion | 1.76% | 0.30x | $25.64 Million |
| Dongwha Pharm.Co.Ltd (000020) | $252.93 Billion | 10.38% | 0.28x | $113.83 Million |
| Yuhan Corp. (000100) | $407.93 Billion | 10.79% | 0.55x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 2.42% | 0.28x | $59.61 Million |
| Yuyu Pharma (000220) | $69.50 Billion | 3.97% | 0.28x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $117.04 Billion | 1.10% | 0.32x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $169.10 Billion | -60.53% | 4.10x | $76.14 Million |
| Samil Pharm (000520) | $127.83 Billion | 1.30% | 1.90x | $127.90 Million |
| Donga Socio Holdings (000640) | $875.86 Billion | 17.02% | 0.60x | $427.15 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $476.78 Million |
About Shinpoong Pharmaceutical Co Ltd
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial dru… Read more